167 related articles for article (PubMed ID: 30943133)
1. Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis.
Tosi GM; Sota J; Vitale A; Rigante D; Emmi G; Lopalco G; Guerriero S; Orlando I; Iannone F; Frediani B; Angotti R; Messina M; Galeazzi M; Vannozzi L; Cantarini L; Fabiani C
Clin Exp Rheumatol; 2019; 37(4):680-683. PubMed ID: 30943133
[TBL] [Abstract][Full Text] [Related]
2. Certolizumab Pegol, a New Anti-TNF-α in the Armamentarium against Ocular Inflammation.
Llorenç V; Mesquida M; Sainz de la Maza M; Blanco R; Calvo V; Maíz O; Blanco A; de Dios-Jiménez de Aberásturi JR; Adán A
Ocul Immunol Inflamm; 2016; 24(2):167-72. PubMed ID: 25325834
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of anti-tumour necrosis factor-α monoclonal antibodies in patients with non-infectious anterior uveitis.
Fabiani C; Vitale A; Rigante D; Emmi G; Lopalco G; Sota J; Vannozzi L; Guerriero S; Bitossi A; Orlando I; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Clin Exp Rheumatol; 2019; 37(2):301-305. PubMed ID: 30719968
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy.
Prieto-Peña D; Calderón-Goercke M; Adán A; Chamorro-López L; Maíz-Alonso O; De Dios-Jiménez Aberásturi JR; Veroz R; Blanco S; Martín-Santos JM; Navarro F; Gallego A; González-Suárez S; Conesa A; García-Valle A; Cordero-Coma M; Pardiñas-Barón N; Demetrio R; Calvo-Río V; Martínez-Taboada VM; Castañeda S; Hernández JL; González-Gay MA; Blanco R
Clin Exp Rheumatol; 2021; 39(1):105-114. PubMed ID: 33124565
[TBL] [Abstract][Full Text] [Related]
5. Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet's Disease.
Fabiani C; Sota J; Rigante D; Vitale A; Emmi G; Vannozzi L; Franceschini R; Bacherini D; Frediani B; Galeazzi M; Tosi GM; Cantarini L
Ocul Immunol Inflamm; 2019; 27(1):58-63. PubMed ID: 28981395
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients.
Martín-Varillas JL; Sanchez-Bilbao L; Calvo-Río V; Adán A; Hernanz I; Gallego-Flores A; Beltran-Catalan E; Castro-Oreiro S; Fanlo P; Garcia Martos A; Torre I; Cordero-Coma M; De Dios JR; García-Aparicio Á; Hernández-Garfella M; Sánchez-Andrade A; García-Valle A; Maiz O; Miguélez R; Rodríguez-Montero S; Urruticoechea A; Veroz R; Conesa A; Fernández-Carballido C; Jovaní V; Mondejar JJ; Martínez González O; Moya Alvarado P; Romero-Yuste S; Rubio-Muñoz P; Peña-Sainz-Pardo E; Garijo-Bufort M; Demetrio-Pablo R; Hernández JL; Blanco R
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36597972
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
Fabiani C; Vitale A; Emmi G; Vannozzi L; Lopalco G; Guerriero S; Orlando I; Franceschini R; Bacherini D; Cimino L; Soriano A; Frediani B; Galeazzi M; Iannone F; Tosi GM; Salvarani C; Cantarini L
Clin Rheumatol; 2017 Jan; 36(1):183-189. PubMed ID: 27853889
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
9. Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis.
Rudwaleit M; Rosenbaum JT; Landewé R; Marzo-Ortega H; Sieper J; van der Heijde D; Davies O; Bartz H; Hoepken B; Nurminen T; Deodhar A
Arthritis Care Res (Hoboken); 2016 Jun; 68(6):838-44. PubMed ID: 26815944
[TBL] [Abstract][Full Text] [Related]
10. The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW.
van der Horst-Bruinsma I; van Bentum R; Verbraak FD; Rath T; Rosenbaum JT; Misterska-Skora M; Hoepken B; Irvin-Sellers O; VanLunen B; Bauer L; Rudwaleit M
RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371433
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor necrosis factor-α therapy in uveitis.
Cordero-Coma M; Sobrin L
Surv Ophthalmol; 2015; 60(6):575-89. PubMed ID: 26164735
[TBL] [Abstract][Full Text] [Related]
12. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis.
Launois R; Avouac B; Berenbaum F; Blin O; Bru I; Fautrel B; Joubert JM; Sibilia J; Combe B
J Rheumatol; 2011 May; 38(5):835-45. PubMed ID: 21239748
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey.
Vavricka SR; Spasojevic M; Rogler G; Schoepfer AM; Seibold F; Borovicka J; Frei P; Zeitz J; Greuter T; Manser C; Scharl M; Misselwitz B; Straumann A; Michetti P; Biedermann L;
Dig Dis; 2017; 35(5):423-432. PubMed ID: 28595194
[TBL] [Abstract][Full Text] [Related]
14. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
[TBL] [Abstract][Full Text] [Related]
15. Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review.
Calvo-Río V; de la Hera D; Blanco R; Beltrán-Catalán E; Loricera J; Cañal J; Ventosa J; Cifrián JM; Ortiz-Sanjuán F; Rueda-Gotor J; González-Vela MC; González-López M; González-Gay MA
Clin Exp Rheumatol; 2014; 32(6):864-8. PubMed ID: 25288110
[TBL] [Abstract][Full Text] [Related]
16. One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.
Harrold LR; Litman HJ; Saunders KC; Dandreo KJ; Gershenson B; Greenberg JD; Low R; Stark J; Suruki R; Jaganathan S; Kremer JM; Yassine M
Arthritis Res Ther; 2018 Jan; 20(1):2. PubMed ID: 29329557
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Safety of Biosimilars in Pediatric Non-infectious Uveitis: Real-Life Data from the International AIDA Network Uveitis Registry.
Tarsia M; Vitale A; Gaggiano C; Sota J; Maselli A; Bellantonio C; Guerriero S; Dammacco R; La Torre F; Ragab G; Hegazy MT; Fonollosa A; Paroli MP; Del Giudice E; Maggio MC; Cattalini M; Fotis L; Conti G; Mauro A; Civino A; Diomeda F; de-la-Torre A; Cifuentes-González C; Tharwat S; Hernández-Rodríguez J; Gómez-Caverzaschi V; Pelegrín L; Babu K; Gupta V; Minoia F; Ruscitti P; Costi S; Breda L; La Bella S; Conforti A; Mazzei MA; Carreño E; Amin RH; Grosso S; Frediani B; Tosi GM; Balistreri A; Cantarini L; Fabiani C
Ophthalmol Ther; 2024 Mar; 13(3):761-774. PubMed ID: 38206518
[TBL] [Abstract][Full Text] [Related]
18. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
Fabiani C; Vitale A; Emmi G; Lopalco G; Vannozzi L; Guerriero S; Gentileschi S; Bacherini D; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Clin Rheumatol; 2017 Jan; 36(1):191-197. PubMed ID: 27981463
[TBL] [Abstract][Full Text] [Related]
19. The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors.
Fabiani C; Vitale A; Emmi G; Sgheri A; Lopalco G; Sota J; Guerriero S; Iannone F; Frediani B; Vannozzi L; Bianco MT; Giovannini V; Tosi GM; Cantarini L
Front Pharmacol; 2019; 10():1468. PubMed ID: 31920658
[No Abstract] [Full Text] [Related]
20. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α.
Ueda N; Tsukamoto H; Mitoma H; Ayano M; Tanaka A; Ohta S; Inoue Y; Arinobu Y; Niiro H; Akashi K; Horiuchi T
Inflamm Bowel Dis; 2013 May; 19(6):1224-31. PubMed ID: 23619715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
